IDEXX LABORATORIES INC /DE
No SEC Form 4 filings for $IDXX in the last 30 days.
See all $IDXX insider activity →IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.
Idexx Laboratories (Nasdaq: IDXX) announced the Catalyst proBNP Test, an in-clinic NT-proBNP assay for both cats and dogs, integrated with its Catalyst point-of-care platform and VetConnect PLUS. The company says it targets a cardiac biomarker used for screening, diagnosis, and monitoring, with availability in North America starting October 2026.
IDEXX Laboratories reported Q2 2026 results driven by 10.3% organic growth in CAG Diagnostics recurring revenue, while U.S. same-store clinical visits fell 1.3%. Management raised full-year organic revenue growth guidance to 8.5% to 9.7% despite a $15 million FX headwind and expects U.S. visits to decline 1.5% in H2. Operating margin rose 110 bps.
Over the past 7 days, alphai's AI scored 2 news stories mentioning IDXX (IDEXX LABORATORIES INC /DE). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent IDXX coverage spans earnings, technology and sector analysis.
Guidance lift plus strong Q2 operating margin and recurring revenue growth suggests upward earnings revisions risk, with FX and wellness-visit softness as key offsets.
The launch expands IDEXX’s connected point-of-care diagnostics footprint in veterinary cardiology, potentially supporting recurring analyzer and test demand.
Guidance raise plus detailed inVue Dx and Cancer Dx adoption metrics suggest improving recurring revenue durability, supporting a bullish near-term repricing versus prior expectations.
Guidance raise and instrument placement/consumables updates suggest improving growth visibility and recurring revenue momentum.
The earnings beat plus raised, tighter FY 2026 EPS and revenue outlook is a direct positive catalyst for IDXX’s near-term valuation and sentiment.
alphai scores every news story that mentions IDXX with an AI model for sentiment and relevance, and aggregates insider trades from IDEXX LABORATORIES INC /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.
7 min readIdexx Laboratories (Nasdaq: IDXX) announced the Catalyst proBNP Test, an in-clinic NT-proBNP assay for both cats and dogs, integrated with its Catalyst point-of-care platform and VetConnect PLUS. The company says it targets a cardiac biomarker used for screening, diagnosis, and monitoring, with availability in North America starting October 2026.
4 min readIDEXX Laboratories reported Q2 2026 results driven by 10.3% organic growth in CAG Diagnostics recurring revenue, while U.S. same-store clinical visits fell 1.3%. Management raised full-year organic revenue growth guidance to 8.5% to 9.7% despite a $15 million FX headwind and expects U.S. visits to decline 1.5% in H2. Operating margin rose 110 bps.
7 min readIDEXX (NASDAQ:IDXX) highlighted Q2 results and product updates on its earnings call. VetLab consumables rose 14% organically, Global Reference Laboratory revenue grew over 10% organically, and Rapid Assay revenue returned to growth. IDEXX placed 5,265 premium instruments, including 1,602 inVue Dx analyzers, and raised 2026 revenue outlook to $4.70-$4.745B and EPS to $14.69-$14.94.
6 min readInvesting.com reports IDEXX Laboratories shares rose 3.9% in pre-open after Q2 2026 results beat expectations. Adjusted EPS was $4.27 vs $3.96 consensus, and revenue was $1.22B vs $1.20B. The company raised and narrowed FY2026 guidance to EPS $14.69-$14.94 and revenue $4.70-$4.75B. U.S. equity futures were also higher.
3 min readIDEXX LABORATORIES INC /DE (IDXX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622041d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ▪ Strong vol
6 min readBank of America said animal health stocks face continued 2Q26 pressure from fewer veterinary visits and higher drug competition. It kept Elanco Animal Health (Elanco) as its top pick with a buy rating, while maintaining neutral ratings on Zoetis and Idexx Laboratories. VetSource data showed Q2 visits down 1.9% YoY and July down 4% YoY. BofA expects FY2026 visits to fall about 2% and sees Elanco pricing rising below Zoetis.
4 min readUBS said Elanco Animal Health is its strongest animal health pick for Q2, citing US pet healthcare momentum through May and early market share gains for Credelio Quattro. UBS expects Q2 revenue above expectations and a potential full-year guidance raise, kept a buy rating and set a $31 price target versus $25.33. UBS was neutral on IDEXX and Zoetis.
2 min readIdexx Laboratories said May 26 it expanded its Fecal Dx antigen testing to detect taeniid tapeworm species (Taenia and Echinococcus). The company says the upgrade can identify up to twice as many infections earlier than fecal flotation and will be added automatically to U.S. and Canada panels starting late June at no extra cost. On May 19, it said SDMA will be integrated into Catalyst CLIPs in June.
2 min readIDEXX Laboratories (IDXX), a $44.3 billion veterinary diagnostics and software company, has underperformed the Nasdaq. Shares are down 27.1% from a 52-week high of $769.98 and down 7.8% over three months, versus the Nasdaq Composite’s 15.8% gain. The stock is down 17.1% in 2026 vs. NASX’s 11.6%. The article cites concerns over moderating companion animal growth and softer demand, plus FX and uneven international demand. Analysts rate it “Moderate Buy” (15 analysts) with a $731.54 mean price targ
4 min read
